The abstract will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation. CervoMed is a clinical-stage ...
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...
IDEAYA will also have a poster presentation with data from a second published abstract providing combination mechanism and pre-clinical synergy data between TOP1-payload based ADCs and IDE161, the ...
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone ...
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial ...
-Flamingo is developing two RNA therapies for cancer: danvatirsen, an antisense oligonucleotide in Phase 2 PEMDA-HN study, and FLM-7523, a MALAT1 inhibitor approaching Phase 1- Dr. Andrew Denker, ...
AD/PD™ 2026 is a leading international conference dedicated to neurodegenerative diseases, convening top medical and scientific experts to present novel findings that advance understanding of disease ...
Presenters: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study and Stephen Gomperts, MD, PhD, Associate Professor of Neurology at Harvard Medical School and Director, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results